Overseas expansion through an exclusive partnership with Novo Nordisk, granting it overseas rights to HS-001 and HS-005 while jointly commercializing the products in Japan and sharing profits. This also includes returning the rights following termination of the partnership and shifting to a policy of securing a new partner or developing the products in-house.